KROS

Keros Therapeutics (NASDAQ:KROS) is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances through late-stage development under…

Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.

LEXINGTON, Mass., Sept.

Initial data expected in the first half of 2027 Initial data expected in the first half of 2027

LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc.

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK).

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc.